

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東新華製藥股份有限公司

Shandong Xinhua Pharmaceutical Company Limited

(a joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 00719)

**UNAUDITED QUARTERLY RESULTS ANNOUNCEMENT
FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2022**

This announcement is made pursuant to rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of Shandong Xinhua Pharmaceutical Company Limited (the “**Company**”) hereby announces the unaudited consolidated results of the Company and its subsidiaries (the “**Group**”) for the 9 months ended 30 September 2022. All financial information set out in this announcement has been prepared in accordance with the CASBE (as defined under the Listing Rules) and has been reviewed and approved by the Board and the Audit Committee of the Board.

The Board and the supervisory committee of the Company and its directors, supervisors and senior management, and persons in charge of the accounting function warrant that there are no false presentations or misleading statements contained in, or material omissions from, this announcement, and severally and jointly accept legal responsibility for the authenticity, accuracy and completeness of the information contained in this announcement.

This announcement is simultaneously available on the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk and the website of the Company at <http://www.xhzy.com>. The third quarterly report of 2022 prepared in accordance with the CASBE will also be available at <http://www.cninfo.com.cn>.

This announcement was prepared in both Chinese and English. In the event of any inconsistencies between the two versions, the Chinese version shall prevail.

1. KEY ACCOUNTING AND FINANCIAL DATA

Item	Jan - Sep 2022 (Unaudited) RMB Yuan	Jan - Sep 2021 (Unaudited) RMB Yuan	Change as compared to the same period last year
Operating income	5,453,318,659.20	4,940,192,936.36	10.39%
Net profit attributable to shareholders of listed company	293,443,285.57	285,336,329.42	2.84%
Net profit attributable to shareholders of listed company after deduction of non-recurring profit and loss	268,235,776.49	251,915,506.34	6.48%
Net cash flow from operating activities	233,819,696.10	230,422,146.43	1.47%
Basic earnings per share (RMB Yuan / Share)	0.45	0.46	(2.17%)

Diluted earnings per share (RMB Yuan / Share)	0.44	0.45	(2.22%)
Ratio of weighted average return on net assets (%)	7.77%	8.54%	Decreased by 0.77 percentage points
Item	As at 30 Sep 2022 (Unaudited) RMB Yuan	As at 31 Dec 2021 (Audited) RMB Yuan	Change as compared to the end of last year
Total assets	8,194,604,106.80	7,332,033,657.98	11.76%
Net assets attributable to the shareholders of listed company	3,972,802,737.29	3,467,941,567.45	14.56%

2. PROFIT AND LOSS ACCOUNT

Consolidated Income Statement

Item	Nine months ended 30 September 2022 (unaudited) RMB Yuan	Nine months ended 30 September 2021 (unaudited) RMB Yuan
I. Gross revenue	5,453,318,659.20	4,940,192,936.36
Including: Operating revenue	5,453,318,659.20	4,940,192,936.36
II. Total operating costs	5,118,017,176.96	4,594,778,972.14
Including: Operating costs	4,034,099,074.08	3,554,645,822.87
Taxes and surcharges	48,744,342.03	44,540,601.94
Selling expenses	453,048,473.38	454,303,699.59
Administration expenses	307,802,300.90	254,945,537.47
R&D cost	258,495,146.14	247,397,181.53
Financial expenses	15,827,840.43	38,946,128.74
Including: Interest expense	37,053,540.27	40,490,300.66
Interest income	6,451,380.72	6,117,637.61
Add: Other income	21,838,095.54	31,702,535.69
Investment income (losses to be listed with brackets)	10,297,156.18	5,867,657.94
Including: Income from investment in affiliates and joint ventures (losses to be listed with brackets)	2,379,340.18	(3,237,828.46)
Credit impairment loss (losses to be listed with brackets)	(2,032,673.39)	(4,756,654.88)
Assets impairment loss (losses to be listed with brackets)	(29,349,965.64)	(34,612,883.67)
Gains from assets disposal (losses to be listed with brackets)	2,027,180.13	593,651.48
III. Operating profits (losses to be listed with brackets)	338,081,275.06	344,208,270.78
Add: non-operating income	1,327,239.36	1,064,918.81
Less: non-operating expenditure	4,800,519.98	5,260,748.01
IV. Total profits (total loss to be listed with brackets)	334,607,994.44	340,012,441.58
Less: income tax expense	31,412,039.38	42,760,206.20
V. Net profits (net loss to be listed with brackets)	303,195,955.06	297,252,235.38
(I) According to operation continuity		

1. Net profit from continued operations (net losses to be listed in brackets)	303,195,955.06	297,252,235.38
2. Net profit from discontinued operations (net losses to be listed in brackets)	-	-
(II) According to ownership		
1. Net profit attributable to the shareholders of parent company	293,443,285.57	285,336,329.42
2. Minority interest	9,752,669.49	11,915,905.96
VI. Net amount of other comprehensive income after tax (net loss to be listed with brackets)	(22,163,814.37)	(48,014,216.93)
Net amount of other comprehensive income after tax attributable to the shareholders of parent company	(23,631,306.61)	(47,948,299.20)
(I) Other comprehensive income not subject to reclassification into profit or loss	(28,787,636.80)	(47,715,273.60)
1.Changes in fair value of other equity instruments investment	(28,787,636.80)	(47,715,273.60)
(II) Other comprehensive income to be reclassified into profit or loss	5,156,330.19	(233,025.60)
1.Conversion difference of foreign currency statement	5,156,330.19	(233,025.60)
Net amount of other comprehensive income after tax attributable to the minority shareholders	1,467,492.24	(65,917.73)
VII. Total comprehensive income	281,032,140.69	249,238,018.45
Total comprehensive income attributable to the shareholders of parent company	269,811,978.96	237,388,030.22
Total comprehensive income attributable to the minority shareholders	11,220,161.73	11,849,988.23
VIII. Earnings per share:		
(I) Basic earnings per share	0.45	0.46
(II) Diluted earnings per share	0.44	0.45

By order of the Board of Directors
Shandong Xinhua Pharmaceutical Company Limited
He Tongqing
Chairman

25 October 2022, Zibo, PRC

As at the date of this announcement, the Board comprises:

Executive Directors:

Mr. He Tongqing (Chairman)

Independent Non-executive Directors:

Mr. Pan Guangcheng

Mr. Zhu Jianwei

Mr. Lo Wah Wai

Non-executive Directors:

Mr. Xu Lie

Mr. Cong Kechun